IDMC recommends continuation of CVOT for Amarin's Vascepa

Amarin Corp. plc (NASDAQ:AMRN) said an IDMC recommended for the second time continuation of the double-blind, placebo-controlled, international Phase III REDUCE-IT trial comparing Vascepa icosapent ethyl plus a statin vs. a statin alone in 8,175 patients with elevated triglyceride levels and other cardiovascular risk factors. The review was triggered by the occurrence of 80% of the target 1,612 primary CV events.

The CV outcomes trial’s primary endpoint is the time to occurrence of a composite of CV death, myocardial infarction (MI), stroke, coronary revascularization or hospitalization for unstable angina. Secondary endpoints include incidence of additional CV events, lipid and lipoprotein levels and subgroup analyses...